Exicure (2H0) AI Stock Analysis

Exicure

(Frankfurt:2H0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt eliminationEliminating debt materially reduces leverage and interest-related pressure, giving Exicure greater financial flexibility than in prior periods. Although the company remains underfunded, a debt-free balance sheet lowers creditor claims and may make future restructuring or capital allocation less constrained.

Negative Factors

No commercial revenueWith no meaningful commercial revenue, Exicure lacks an internally generated funding engine and remains dependent on financing or potential collaborations. Persistent negative gross profit and losses make self-sustaining operations difficult and leave future development reliant on external capital.

Exicure (2H0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 6.61M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.8
Beta (1Y): -1.27
Revenue Growth: ―
EPS Growth: 27.59%
Country: Germany
Employees: 1
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Exicure Business Overview & Revenue Model

Company Description

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combi...

Exicure Risk Analysis

Exicure disclosed 22 risk factors in its most recent earnings report. Exicure reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.It is uncertain if or when we will recognize any royalties or license payments arising from our historical biotechnology intellectual property and other assets.Q3, 2024

Exicure Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:2H0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
UNCY	41Neutral	$104.18M	-2.23	-88.81%	―	―	43.63%
CRBU	29Underperform	$45.37M	-0.39	-89.11%	―	10.02%	39.66%

* Healthcare Sector Average

Performance Comparison

DE:2H0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:2H0	Exicure	0.79	-2.93	-78.76%
UNCY	Unicycive Therapeutics, Inc.	3.74	-0.70	-15.77%
CRBU	Caribou Biosciences, Inc.	0.42	-2.01	-82.59%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Exicure AI Stock Analysis